Drug therapy in older people with heart failure

Editor – We read with interest the review article by Mukhtar and Jackson entitled Drug therapy in older adults (part 2).\(^1\) In the article the authors provide an overview on the drug treatment of heart failure in older patients. However, we were surprised that digoxin, one of the oldest drugs in the management of heart failure was not mentioned as a treatment option. Clinical evidence is in favour of digoxin in diastolic heart failure as well as systolic heart failure through improvement of early diastolic function and possible reduction in sympathetic humoral activity. The benefits are not restricted to patients with heart failure in atrial fibrillation but also in sinus rhythm. In a systematic review of 13 trials which included over 7,000 patients with heart failure in sinus rhythm, digitalis had a positive effect on improving symptoms and reducing hospitalisation.\(^2\)

The earlier Digitalis Investigation Group trial had also showed, in addition to 6% less hospitalisation in the treatment, a trend toward a beneficial effect of digoxin in pump failure death, but this was offset by mortality from non-cardiovascular causes\(^1\).

Therefore in older patients with moderately severe heart failure who remain symptomatic despite optimum treatment with diuretics, angiotensin-converting-enzyme inhibitors and beta blockers, it is worthwhile considering the addition of digoxin. It is important to point out that the benefits of digoxin occur with low maintenance dosage which is usually between 62.5–125 µg daily.

The benefits of digoxin mentioned above cannot be over-emphasised in the vast majority of the older frailer population with heart failure. This is important as the NHS is aiming towards keeping the frail elderly in their own environment for as long as possible rather than hospitalisation. Clinicians working in acute frailty units are likely to come across more of these patients and can best serve this cohort of patients well by asking why they cannot be on digoxin. Every little helps especially on a frailty ward!

References

1 Mukhtar O, Jackson SH. Drug therapies in older adults (part 2). Clin Med 2015;15:155–9.
2 Hood WB, Dans AL, Guyatt GH et al. Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. J Card Fail 2004;10:155–164.
3 The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525–33.

GREGORY BABALOLA
Princess Royal University Hospital, Orpington, UK

AZA ARDULLA
Princess Royal University Hospital, Orpington, UK

A cough that doesn’t fit the mould

Editor – We read with interest the lesson of month entitled A cough that doesn’t fit the mould (Clin Med 2015;15:492–4). This is an interesting case report, which we believe highlights the difficulty in making a diagnosis and classifying Aspergillus-related pulmonary disease. Baggott et al have made a diagnosis of Aspergillus tracheobronchitis and mention that it is part of the spectrum of invasive Aspergillus disease. We believe it would be worth adding that both saprophytic (non-invasive) and invasive forms of Aspergillus tracheobronchitis exist.\(^1,2\) The latter requires the demonstration of fungal hyphae invading the bronchial mucosa, which was not demonstrated in this case. Where fungal hyphae are found in the bronchial tree without invasion this could be due to obstructing bronchial aspergilloma, which requires the absence of allergic disease,\(^1\) or mucoid impaction that is a non-specific sign of Aspergillus bronchial disease and is also a feature of allergic bronchopulmonary aspergillosis (ABPA). The case presented by Baggott et al had mucoid impaction resulting in obstruction and collapse of the right middle lobe. However, the patient developed features of an allergic reaction to Aspergillus evidenced by the positive grade-III specific Aspergillus IgE, high total IgE level (1,519 kU/L) and

References

1. Mukhtar O, Jackson SH. Drug therapies in older adults (part 2). Clin Med 2015;15:155–9.
2. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525–33.
Letters to the editor

pulmonary eosinophilia (1.94x10^9/L). Therefore, we wonder if this patient developed seropositive ABPA following sensitisation and repeated exposure to Aspergillus species. What is interesting in the presented case is the absence of pre-existing respiratory disease, as ABPA does not usually present as an acute primary condition. ABPA is more often found in patients with asthma and cystic fibrosis, and certainly the presence of asthma is considered essential for the diagnosis of classical ABPA; however it is not infrequent that it is reported in individuals without a past history of asthma.1–5

References
1 Krenke R, Grabczak EM. Tracheobronchial manifestations of Aspergillus infections. ScientificWorldJournal 2011;11:2310–29.
2 Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax 2014;70:270–7.
3 Glancy JJ, Elder JL, McAleer R. Allergic bronchopulmonary fungal disease without clinical asthma. Thorax 1981;36:345–9.
4 Roth R. Allergic bronchopulmonary aspergillosis presenting as chronic cough in an elderly woman without previously documented asthma. Perm J 2013;17:e103–8.
5 Matsuoka H, Uzu T, Koyama M et al. Allergic bronchopulmonary aspergillosis presenting with cough variant asthma with spontaneous remission. Respir Med CME 2011;4:175–7.

RICARDO J JOSE
Respiratory specialist registrar, Centre for Inflammation and Tissue Repair, University College London, London, UK; and Department of Respiratory Medicine, Homerton University Hospital, London, UK

ANGSHU BHOWMIK
Consultant respiratory physician, Department of Respiratory Medicine, Homerton University Hospital, London, UK

JEREMY S BROWN
Professor of respiratory infection and Consultant respiratory physician, Centre for Inflammation and Tissue Repair, University College London, London, UK; and Department of Respiratory Medicine, University College Hospital, London, UK

Response
Editor – We would like to thank the correspondents for their interest in our case report. We are in complete agreement that this case illustrates the difficulty in diagnosing the various respiratory conditions that can be caused by Aspergillus and the considerable overlap between them. We also agree that the distinction between non-invasive and invasive forms of Aspergillus tracheobronchitis is important and in our case, the disease was non-invasive.

We read with interest their comments that allergic bronchopulmonary aspergillosis (ABPA) has been reported in individuals without a history of asthma,1 and whether this patient had developed ABPA rather than Aspergillus tracheobronchitis as we proposed. ABPA was one of the differential diagnoses considered while the patient was under our care; however several factors influenced our final diagnosis, based on the diagnostic criteria of Rosenberg and Patterson.2,3

Radiologically, no fleeting opacities or bronchiectasis were present on chest radiograph or computed tomography of the chest. In this case, the radiological manifestation of disease was limited to right middle lobe collapse, which subsequently resolved. While he did develop features of allergic sensitisation to Aspergillus – demonstrated by raised total serum IgE, Aspergillus specific IgE and serum eosinophilia – we felt this was a consequence of his exposure to a significant burden of Aspergillus spores, as demonstrated by the fungal hyphae from his mucous plug. Finally, his response to treatment was more rapid than is usually seen in ABPA.

We would like to thank the correspondents for highlighting that ABPA can rarely be seen in patients without a diagnosis of asthma or cystic fibrosis, further illustrating the complexity of Aspergillus-related pulmonary disease.

References
1 Glancy JJ, Elder JL, McAleer R. Allergic bronchopulmonary fungal disease without clinical asthma. Thorax 1981;36:345–9.
2 Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M, Harris KE. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med 1977;86:405–14.
3 Patterson R, Greenberger PA, Halwig JM, Liootta JL, Roberts M. Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. Arch Intern Med 1986;146:916–8.

CHRISTINA RAGGOTT
Respiratory specialist registrar, North Bristol Lung Centre, Southmead Hospital, Bristol, UK

CHARLES SHARP
Respiratory specialist registrar, Academic Respiratory Unit, University of Bristol, Bristol, UK

NIDHI BHATT
Consultant histopathologist, Department of Histopathology, University Hospitals Bristol, Bristol, UK

MARTIN PLUMMERIDGE
Consultant respiratory physician, North Bristol Lung Centre, Southmead Hospital, Bristol, UK

HUZAIFA ADAMALI
Consultant respiratory physician, North Bristol Lung Centre, Southmead Hospital, Bristol, UK